Vartan Bekerian
Psychiatric/Mental Health · Culver City, CANPI 1790558187
Payments from drug & device makers
Across 121 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Alkermes, Inc.$369
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$342
- Neurocrine Biosciences, Inc.$154
- Otsuka America Pharmaceutical, Inc.$146
- E.r. Squibb & Sons, L.L.C.$123
- plus $124 from 2 others
What the payments were for
- Food & beverage$2,684100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 75 | $1,426 |
| Alkermes, Inc. | 17 | $369 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $342 |
| Neurocrine Biosciences, Inc. | 9 | $154 |
| Otsuka America Pharmaceutical, Inc. | 1 | $146 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Vanda Pharmaceuticals Inc. | 5 | $94 |
| Lundbeck LLC | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$652
- LYBALVI$504
- CAPLYTA$167
- ABILIFY MAINTENA$146
- ABILIFY ASIMTUFII$146
- COBENFY$123
How this compares
$2,684 in reported general payments places this provider in the 80th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine OdtClozapine | 40 | $18,069 |
| Quetiapine Fumarate | 126 | $2,796 |
| Olanzapine OdtOlanzapine | 20 | $2,497 |
| Divalproex Sodium | 37 | $1,712 |
| Mirtazapine | 53 | $1,368 |
| Risperidone | 54 | $1,350 |
| Buspirone Hcl | 62 | $1,313 |
| Olanzapine | 60 | $1,295 |
| Haloperidol | 19 | $1,143 |
| Clozapine | 28 | $1,077 |
| Benztropine Mesylate | 58 | $1,041 |
| Trazodone Hcl | 68 | $692 |
| Sertraline Hcl | 53 | $599 |
| Lorazepam | 64 | $519 |
| Zolpidem Tartrate | 22 | $348 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Culver City
- Joseph WeigelCulver City$18K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.